| GDS2545 |
Metastatic prostate cancer (HG-U95A) |
Expression profiling by array, count, 4 tissue sets |
GPL8300 |
GSE6919 |
171 |
| GDS2546 |
Metastatic prostate cancer (HG-U95B) |
Expression profiling by array, count, 4 tissue sets |
GPL92 |
GSE6919 |
167 |
| GDS2547 |
Metastatic prostate cancer (HG-U95C) |
Expression profiling by array, count, 4 tissue sets |
GPL93 |
GSE6919 |
164 |
| GDS3289 |
Prostate cancer progression at the cellular level |
Expression profiling by array, log2 ratio, 2 cell type, 6 disease state, 14 other sets |
GPL2013 |
GSE6099 |
104 |
| GDS4395 |
External beam radiation therapy effect on prostate cancer patients: peripheral white blood cells |
Expression profiling by array, count, 20 individual, 2 protocol, 8 time sets |
GPL570 |
GSE30174 |
80 |
| GDS4109 |
Recurrent and non-recurrent prostate cancer primary tumors |
Expression profiling by array, count, 2 disease state sets |
GPL96 |
GSE25136 |
79 |
| GDS2384 |
Xenograft model of prostate carcinoma progression |
Expression profiling by array, log2 ratio, 4 disease state, 3 other, 10 protocol, 14 specimen sets |
GPL3349 |
GSE4084 |
52 |
| GDS5267 |
Cyclin-dependent kinase inhibitor R547 effect on prostate cancer cell line: dose response and time course |
Expression profiling by array, count, 3 agent, 4 dose, 4 time sets |
GPL570 |
GSE15392 |
45 |
| GDS1746 |
Primary epithelial cell cultures from prostate tumors |
Expression profiling by array, count, 7 disease state, 2 protocol sets |
GPL96 |
GSE3868 |
30 |
| GDS4952 |
BET bromodomain inhibitor I-BET762 effect on prostate cancer cell lines: dose response |
Expression profiling by array, count, 4 cell line, 3 dose sets |
GPL570 |
GSE56352 |
24 |
| GDS4114 |
Reactive stroma of breast and prostate cancer |
Expression profiling by array, transformed count, 2 disease state, 2 tissue sets |
GPL570 |
GSE26910 |
24 |
| GDS4824 |
Prostate cancer |
Expression profiling by array, count, 2 disease state, 3 genotype/variation sets |
GPL570 |
GSE55945 |
21 |
| GDS1390 |
Prostate cancer progression after androgen ablation |
Expression profiling by array, count, 2 disease state sets |
GPL96 |
GSE2443 |
20 |
| GDS1439 |
Prostate cancer progression |
Expression profiling by array, count, 3 disease state sets |
GPL570 |
GSE3325 |
19 |
| GDS4964 |
Telomere-elongated, prostate cancer cells |
Expression profiling by array, transformed count, 2 genotype/variation, 2 protocol sets |
GPL570 |
GSE41559 |
16 |
| GDS4158 |
LNCap prostate cancer cell line response to loss of COnstitutive Photomorphogenic-1 and ETV1 |
Expression profiling by array, transformed count, 3 genotype/variation sets |
GPL570 |
GSE27914 |
16 |
| GDS4159 |
LNCap prostate cancer cell line response to loss of COnstitutive Photomorphogenic-1, ETV1 and c-JUN |
Expression profiling by array, transformed count, 3 genotype/variation sets |
GPL570 |
GSE27914 |
15 |
| GDS3358 |
Androgen deprivation effect on LNCaP prostate cancer cells: time course |
Expression profiling by array, count, 2 growth protocol, 6 time sets |
GPL570 |
GSE8702 |
15 |
| GDS535 |
Prostate cancer antiandrogen resistance |
Expression profiling by array, count, 2 cell type sets |
GPL91 |
GSE847 |
14 |
| GDS6100 |
MicroRNA-135b overexpression effect on prostate cancer cell line: time course |
Expression profiling by array, transformed count, 2 protocol, 3 time sets |
GPL10558 |
GSE57820 |
12 |
| GDS4957 |
FOXA1 overexpression effect on prostate cancer cell line |
Expression profiling by array, transformed count, 2 protocol sets |
GPL10558 |
GSE49153 |
12 |
| GDS4951 |
Lysophosphatidic acid effect on breast and prostate cancer cell lines |
Expression profiling by array, count, 2 agent, 3 cell line sets |
GPL570 |
GSE56265 |
12 |
| GDS4107 |
KUCaP-2 xenograft model of castration-resistant prostate cancer: various stages |
Expression profiling by array, transformed count, 3 development stage sets |
GPL570 |
GSE21887 |
12 |
| GDS3973 |
Docetaxel resistant prostate cancer cell line |
Expression profiling by array, transformed count, 4 cell line sets |
GPL570 |
GSE33455 |
12 |
| GDS3861 |
Synthetic androgen R1881 effect on transcription factor SRF-deficient prostate cancer cells |
Expression profiling by array, transformed count, 2 agent, 2 protocol sets |
GPL570 |
GSE22606 |
12 |
| GDS2971 |
Hemiasterlin analog HTI-286 effect on docetaxel-resistant prostate cancer cell line |
Expression profiling by array, log2 ratio, 2 agent sets |
GPL3877 |
GSE8325 |
12 |
| GDS5072 |
High grade prostate cancer |
Expression profiling by array, count, 2 disease state, 3 other sets |
GPL570 |
GSE45016 |
11 |
| GDS5440 |
Androgen effect on carboxyl terminal-binding protein 2-deficient prostate cancer cell line |
Expression profiling by array, transformed count, 2 agent, 4 genotype/variation sets |
GPL6244 |
GSE58309 |
10 |
| GDS3111 |
Prostate cancer cell line response to dihydrotestosterone: time course |
Expression profiling by array, count, 2 agent, 3 time sets |
GPL570 |
GSE7868 |
9 |
| GDS3634 |
miR-205 expression effect on prostate cancer cell line |
Expression profiling by array, count, 2 protocol sets |
GPL6104 |
GSE11701 |
8 |
| GDS3095 |
Zinc effect on malignant and non-malignant prostate cell lines: time course |
Expression profiling by array, count, 2 agent, 2 cell line, 4 time sets |
GPL2986 |
GSE5590 |
8 |
| GDS2034 |
Prostate cancer cell line LNCaP response to synthetic androgen R1881: time course |
Expression profiling by array, log2 ratio, 4 time sets |
GPL3349 |
GSE4027 |
8 |
| GDS1736 |
Arachidonic acid effect on prostate cancer cells |
Expression profiling by array, count, 2 agent sets |
GPL96 |
GSE3737 |
8 |
| GDS1699 |
Androgen sensitive and insensitive prostate cancer cell lines: expression profiles |
Expression profiling by array, log2 ratio, 8 cell line, 2 cell type sets |
GPL3341 |
GSE4016 |
8 |
| GDS5805 |
Peptidyl-prolyl cis/trans isomerase Pin1 deficiency effect on prostate cancer cells |
Expression profiling by array, transformed count, 2 cell line, 3 protocol sets |
GPL6244 |
GSE67457 |
6 |
| GDS5222 |
U2OS osteosarcoma cell line response to strigolactone analogs ST362 and MEB55: 24 hours |
Expression profiling by array, count, 3 agent sets |
GPL10558 |
GSE54820 |
6 |
| GDS5221 |
U2OS osteosarcoma cell line response to strigolactone analogs ST362 and MEB55: 6 hours |
Expression profiling by array, count, 3 agent sets |
GPL10558 |
GSE54820 |
6 |
| GDS5173 |
G-protein coupled receptor kinase 3 expression effect on prostate cancer cell line |
Expression profiling by array, count, 2 agent sets |
GPL6883 |
GSE36022 |
6 |
| GDS4124 |
Genetic reprogramming of prostate cancer-associated stromal cells |
Expression profiling by array, transformed count, 5 cell type, 2 protocol sets |
GPL570 |
GSE35373 |
6 |
| GDS4121 |
Hepatocyte growth factor treatment of prostate cancer DU145 cell line: time course |
Expression profiling by array, count, 2 agent, 3 time sets |
GPL570 |
GSE16659 |
6 |
| GDS4113 |
Late passage LNCaP prostate tumor cells treated with androgen receptor shRNA or androgen R1881 |
Expression profiling by array, count, 3 genotype/variation sets |
GPL570 |
GSE22483 |
6 |
| GDS2865 |
Metastatic prostate tumor model |
Expression profiling by array, count, 2 disease state sets |
GPL96 |
GSE7930 |
6 |
| GDS4123 |
Isoflavone and 3,3’-diindolylmethane effect on C4-2B prostate cancer cells |
Expression profiling by array, count, 3 agent, 4 time sets |
GPL570 |
GSE35324 |
5 |
| GDS5804 |
PI3K/mTOR Inhibitor NVP-BEZ235 and taxotere effects on prostate cancer xenograft tumors |
Expression profiling by array, count, 4 agent sets |
GPL570 |
GSE49232 |
4 |
| GDS5606 |
Androgen effect on runt-related transcription factor 1-deficient prostate cancer cell line |
Expression profiling by array, transformed count, 2 agent, 2 genotype/variation sets |
GPL6244 |
GSE62454 |
4 |
| GDS5373 |
miR-221 expression effect on prostate cancer cell line |
Expression profiling by array, count, 2 protocol sets |
GPL570 |
GSE45627 |
4 |
| GDS4846 |
MED1 overexpression effect on prostate cancer cell line |
Expression profiling by array, count, 2 protocol sets |
GPL571 |
GSE41150 |
4 |
| GDS4829 |
VprBP depletion effect on prostate cancer cell line |
Expression profiling by array, count, 2 genotype/variation sets |
GPL10558 |
GSE50414 |
4 |
| GDS3797 |
beta-TrCP inhibition and androgen ablation effects on prostate cancer cell line LAPC4 |
Expression profiling by array, transformed count, 2 genotype/variation, 2 growth protocol sets |
GPL571 |
GSE19141 |
4 |
| GDS1697 |
DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine effect on prostate cancer cell lines |
Expression profiling by array, log2 ratio, 4 cell line sets |
GPL3295 |
GSE4089 |
4 |
| GDS1423 |
Lunasin effect on prostate epithelial cells |
Expression profiling by array, count, 2 agent, 2 disease state sets |
GPL96 |
GSE2992 |
4 |
